Natural Health Trends Corp. — Q1 2012 Form 10-Q
Reporting period: Three months ended March 31, 2012; comparisons are with Q1 2011 unless otherwise stated. The company sells personal care, wellness and quality-of-life products through e-commerce and an independent distributor network. Amounts below are in U.S. dollars; financial statement amounts are in thousands unless noted.
Financial performance and position
| Metric | Q1 2012 | Q1 2011 / prior date |
|---|---|---|
| Net sales | $9.09 million | $5.18 million |
| Gross profit / margin | $6.69 million / 73.6% | $3.65 million / 70.4% |
| Distributor commissions | $3.69 million / 40.6% of sales | $1.76 million / 34.0% |
| SG&A | $2.44 million | $2.03 million |
| Operating income (loss) | $551,000 | $(378,000) |
| Net income (loss) attributable to common stockholders | $503,000; diluted EPS $0.04 | $(476,000); diluted EPS $(0.04) |
| Cash from operating activities | $860,000 | $52,000 |
| Cash and cash equivalents | $2.76 million at March 31, 2012 | $1.62 million at December 31, 2011 |
Operating margin was 6.1%, versus negative 7.3% a year earlier. Gross margin improved mainly because of a Russian-market price increase and lower Russian logistics fees. Other expense was $63,000, including a $64,000 foreign-exchange loss; Q1 2011 other expense was $95,000, including a $98,000 foreign-exchange loss.
Total assets were $7.30 million and current liabilities were $7.54 million at quarter-end. The company reported a $2.5 million working-capital deficit and a current ratio of 0.66:1 (0.81:1 excluding deferred revenue). It generated $229,000 from investing activities, largely from the release of restricted cash, and had no financing cash flows. The filing reports no current borrowings on the balance sheet; historical convertible debentures had been redeemed in 2009.
Material changes and management commentary
- Sales rose 76% year over year. Hong Kong sales increased 158% to $6.13 million and represented 67.4% of total sales; Russia sales increased to $1.57 million. Active distributors rose to approximately 20,000 from 16,000 a year earlier.
- Management attributed Hong Kong growth largely to a Macau marketing event and new recognition-program incentives. These programs were expected to continue at least through Q2 2012; management cautioned that prior-year anniversary timing may affect comparisons and that year-to-date comparisons through June and September may better indicate trends.
- Commissions increased to 40.6% of sales, largely reflecting Hong Kong recognition-program promotions and changes to the Russian compensation plan. SG&A rose 20%, including higher audit, card-processing, event and employee-related costs.
- The Hong Kong shipper announced an average fee increase of 8%. Management said it was developing mitigation plans and estimated a potential gross-margin impact of up to one percentage point in Q2.
- Management believed cash on hand and operating cash flows would fund normal operations and commitments for at least 12 months, assuming no significant unforeseen expense or further revenue decline. It did not expect external funding to be necessary, but disclosed no significant unused liquid-asset sources.
Risks, contingencies and unusual items
- About 95% of sales were generated outside North America. The business is highly concentrated in Hong Kong, and most Hong Kong revenue comes from products delivered to members in China. The company lacks a Chinese direct-selling license; its applications had not materially progressed, and it could not predict whether or when a license would be obtained. Chinese regulatory interpretation or enforcement could restrict e-commerce or member activity.
- Foreign-currency movements, economic and political conditions, direct-selling and product regulations, distributor conduct, competition, product acceptance and potential cash-flow deterioration are among the disclosed business risks.
- In South Korea, a mutual-aid contract supports consumer indemnity claims; $88,000 was held in related restricted assets, and management considered use of the funds remote. No contingent obligation under registration-payment arrangements had been recognized at March 31, 2012; a potential payment of up to approximately $60,000 is described under specified conditions.
- The company was considering a royalty and license arrangement with Broady Health Sciences, an entity connected to a director, for the Restor product. Proposed terms included reimbursement of up to $42,000 and a 2.5% royalty; estimated royalties for 2011 and Q1 2012 were approximately $17,000. No definitive agreement was reported.
- No legal proceedings were reported. Management concluded disclosure controls were effective as of March 31, 2012, with no material quarter-specific change in internal control over financial reporting.
Most important facts for investors to verify
- Whether Q1’s sharp Hong Kong-led sales growth and incentive-driven demand continued after the quarter, and how much sales were pulled forward by events or promotions.
- Whether higher distributor commissions and the announced Hong Kong shipping-fee increase reduce future margins.
- Liquidity trends, including the working-capital deficit, cash conversion and management’s assumptions supporting its 12-month liquidity assessment.
- Developments in Chinese licensing, e-commerce rules and enforcement that could affect the company’s concentrated Greater China business.
- Whether the proposed related-party Restor royalty and license agreement was finalized, and its resulting costs and terms.